A recent study suggests that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a leading medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Users buying such treatments need to be aware of the danger of rapid weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to original weight within about 18 months.
Analyzing Treatments
The analysis, which looked at 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone usually experience a slower creep back—around 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Experts suggest the mechanism of the jabs is key to understanding the accelerated weight return.
These medications imitate a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than normal could lead to the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication results in hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Issue?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of relapse, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
People who have come off the medication describe a intense resurgence of appetite.
"It felt as if a trigger flipping and I was suddenly ravenous," said a patient.
The struggle is compounded if patients have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Figures indicate that a significant number of people in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success relies on integrated lifestyle support.
